市场调查报告书
商品编码
1383331
2030 年人类微生物组市场预测:按产品、疾病、类型、应用和地区进行的全球分析Human Microbiome Market Forecasts to 2030 - Global Analysis By Product (Medical Foods, Prebiotics, Probiotics, Symboitics and Other Products), Disease, Type, Application and By Geography |
根据 Stratistics MRC 的数据,2023 年全球人类微生物组市场规模将达到 8 亿美元,预计到 2030 年将达到 63 亿美元,预测期内年复合成长率为 34.1%。
「人类微生物组市场」一词定义了专注于人类微生物组的彻底研究、分析和商业性应用的生物技术和医疗领域。它由研究、诊断、治疗和个人化医疗等各个领域组成,旨在了解人体与其栖息的微生物之间的共生相互作用。
根据美国癌症协会估计,2022 年美国将报告约 1,918,030 例新癌症病例。此外,根据Globocan 2020统计,新增癌症病例数为274,364例,预计2040年将达到400,564例。
过去几十年来,微生物组研究取得了重大进展,使我们对微生物组与人类健康和疾病的关係的理解发生了重大变化。此外,由于高通量序列测定方法和强大的生物资讯工具,现在可以对人体内存在的大量微生物群落进行彻底分析和表征。
主要问题之一是微生物产品和治疗方法缺乏透明和统一的法规流程。基于微生物的产品和治疗方法缺乏简单而统一的法律规范可能会限制市场扩张并增加进入障碍。然而,微生物群落的多样性和人类微生物组的动态性质在评估产品安全性和功效时给法规机构带来了挑战。
肥胖、糖尿病、发炎性肠道疾病疾病和自体免疫疾病等慢性疾病在世界各地变得越来越普遍。因此,医学相关人员和学者正在探索以微生物为基础的疗法,以便更好地了解和管理这些慢性疾病。此外,许多发育技术都涉及恢復慢性病患者的微生物平衡,包括益生菌、粪便微生物移植 (FMT) 和微生物组控制。
微生物组研究领域需要在研发 (R&D) 方面进行大量投资,以充分了解人类微生物组的复杂性并开发基于此的产品和排除项。益生菌和益生元等微生物治疗方法的开发、资料分析、临床试验和微生物组定序都包含在这些支出中。然而,可用产品和治疗方法的多样性受到高昂的研发成本的阻碍,这可能会阻止小型企业和新兴企业进入市场。
全球范围内的临床试验研究因 COVID-19 大流行而受到严重干扰。鑑于研究通常包括贫困阶级,他们最容易接触到 COVID-19,这一点尤其重要。同样,COVID-19 已经并可能对其他公司的营运产生负面影响,包括微生物药物和诊断设备的临床前研究和临床试验。
预计益生菌产业在预测期内将达到最高水准。益生菌是活的微生物,当以足够的比例给药宿主时,可以透过恢復或维持肠道菌丛来改善或维持宿主的整体健康。由于它能够促进免疫健康、帮助消化和影响一般健康的许多组成部分,因此它变得非常受欢迎。此外,随着人们越来越重视预防性健康和保健,随着客户寻求针对医疗问题的微生物友善治疗方法,益生菌产业预计将会成长。
随着人们越来越认识到人类微生物组在健康和疾病中发挥的重要作用,诊断领域预计将在预测期内呈现最高成长率。由于定序技术和生物资讯学的进步,微生物组诊断可以更深入地了解人体微生物种群,从而实现个体化和精确的治疗。此外,微生物组诊断由于其在支持疾病早期检测、指导个体化治疗策略和评估干预措施成功与否方面的潜力而在医疗保健领域变得越来越普及。
北美地区占最大份额,原因在于其完善的医疗设施网络、大公司加大对开发更先进技术的投资以及加速新药开发进程。这一领域正变得更加活跃。此外,人类微生物组治疗正在引起人们的关注,与文明病变得越来越普遍,人类微生物组的次世代定序和技术进步正在取得进展。所有这些因素都促进了该地区的市场成长。
由于消费者对益生菌、益生元和微生物组相关产品的兴趣不断增加,预计亚太地区将实现盈利增长。这是因为微生物组在消化、营养健康和整体健康方面的重要性正在广泛认可。此外,亚太地区微生物组科学领域的研发活动正在增加,特别是在中国、日本和韩国等大力投资生物技术和生命科学的国家。
According to Stratistics MRC, the Global Human Microbiome Market is accounted for $0.8 billion in 2023 and is expected to reach $6.3 billion by 2030 growing at a CAGR of 34.1% during the forecast period. The term "Human Microbiomes Market" defines the area of biotechnology and healthcare that focuses on the thorough study, analysis, and commercial applications of the human microbiome, which is the enormous and diverse community of microorganisms that exists both inside and outside the human body. To comprehend the symbiotic interaction between the human body and its resident microorganisms, it comprises a variety of fields, including research, diagnostics, treatments, and customized medicine.
According to the American Cancer Society, 2022 estimates, there are about 1,918,030 new cases of cancer will be reported in the United States in 2022. Additionally, according to the Globocan 2020 statistics, there are 274,364 new cases of cancer and is expected to reach 400,564 new cases by 2040.
An enormous shift has occurred in the comprehension of the human microbiome's involvement in human health and disease as a result of the substantial advancements made in the investigation of it over the past few decades. Additionally, the tremendous community of microorganisms that reside inside the human body has been thoroughly analyzed and characterized because of high-throughput sequencing methods and powerful bioinformatics tools.
The lack of transparent and uniform regulatory processes for microbiome-based products and treatments is one of the main problems. The absence of simple and uniform regulatory frameworks for microbiome-based products and treatments may limit market expansion and increase entry hurdles. However, the variety of microbial communities and the dynamic nature of the human microbiome present difficulties for regulatory authorities when evaluating products' safety and efficacy.
Globally, chronic illnesses such as obesity, diabetes, inflammatory bowel diseases, and autoimmune disorders are becoming more prevalent. As a result, in order to better understand and manage these chronic diseases, medical professionals and academics are exploring microbiome-based therapies. Additionally, the restoration of microbial equilibrium among individuals with chronic illnesses involves a number of developing methods, including probiotics, fecal microbiota transplantation (FMT), and microbiome regulation.
In order to fully comprehend the complexity of the human microbiome as well as develop products and eliminates that are based on it, the field of microbiome research requires significant investments in research and development (R&D). The creation of microbiome therapies like probiotics and prebiotics, as well as data analysis, clinical trials, and microbiome sequencing, are all included in these expenditures. However, the variety of products and treatments available may be hampered by the high cost of R&D, which may prevent smaller businesses and startups from entering the market.
Clinical trial research has been significantly hampered worldwide by the COVID-19 epidemic. Given that studies usually include poor people who are most in danger from COVID-19 exposure, this is very important. Similarly, COVID-19 has had a detrimental effect and might still have one on the operations of other companies, including their preclinical research and clinical testing of microbiome-based drugs and diagnostic instruments.
The segment for probiotics is anticipated to be the largest during the forecast period. Probiotics are living microorganisms that, when administered to a host in sufficient proportions, improve or maintain the host's overall health by restoring or maintaining their intestinal microbiome. Due to their significance in promoting immune health, boosting digestion, and potentially affecting a number of different elements of general wellbeing, they have grown tremendously popular. Furthermore, with an increasing emphasis on preventive health and wellness, the probiotics sector is anticipated to develop as customers look for microbiome-friendly remedies to their medical issues.
Due to the growing awareness of the crucial role played by the human microbiome in health and illness, the diagnostics segment is anticipated to have the highest growth rate throughout the projection period. Microbiome diagnostics can offer a deeper comprehension of the microbial populations within the body due to developments in sequencing technologies and bioinformatics, enabling personalized and precise therapy. Moreover, microbiome diagnostics are also becoming more popular in healthcare due to their potential to support early disease detection, guide individualized treatment strategies, and assess the success of interventions.
North America held the largest share due to an established network of healthcare facilities, greater investment from major firms in developing more advanced technology, accelerating the process of creating new drugs, and a rise in research efforts in this field. Additionally, human microbiome treatments are getting more attention, lifestyle ailments are becoming more prevalent, and next-generation sequencing and the human microbiome are experiencing more technological advancements. These factors are all contributing to the market's growth in the region.
Due to growing consumer interest in probiotics, prebiotics, and microbiome-focused products, the Asia-Pacific area is predicted to experience profitable growth. This is due to digestion, nutritional wellness, and the importance of the microbiome in overall well-being which are becoming more widely recognized. Additionally, the Asia Pacific area has experienced a rise in research and development activities in the field of microbiome science, especially in nations like China, Japan, and South Korea that have made significant investments in biotechnology and the life sciences.
Some of the key players in Human Microbiome market include: Seres Therapeutics, Second Genome Inc., Osel Inc., Exeliom Biosciences SAS, Ginkgo Bioworks, Finch Therapeutics Group Inc., Evelo Biosciences Inc, DuPont, Axial Biotherapeutics, Inc. and Astarte Medical.
In January 2023, Genetic Analysis AS, a research driven diagnostic company that focuses on innovative diagnostic solutions with microbiota analysis, entered into an agreement with Microbiome Research Pvt. Ltd., a India-based microbiome company, for launching a test service portfolio based on the GA-map Dysbiosis Test, and thus, making it the first CE-IVD marked standardized gut microbiome test.